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Selected Abbreviations and Acronyms:
MS - metabolic syndrome 
T2DM - type 2 diabetes mellitus (T2DM) 
CVD - cardiovascular disease 
WHO - World Health Organization 
TAG - triacylglycerol 
NEFA - nonesterifi ed fatty acids 
TNF-α  - tumor necrosis factor α 
LEPR - leptin receptors 
LMW - low molecular weight 
HMW - high molecular weight   
HDL – high density lipoprotein
LDL – low density lipoprotein
VLDL – very low density lipoprotein
CETP - cholesteryl ester transfer protein 
LPL - lipoprotein lipases
LDLR - LDL receptor 
MUFA - monounsaturated fatty acid
PUFA - polyunsaturated fatty acid
SFA - saturated fatty acid
PPARα  - peroxisome proliferator-activated receptor α .
CLA - conjugated linoleic acid
 
Introduction
The metabolic syndrome (MS) represents a multi-compo-
nent disorder characterized by abdominal obesity, insulin re-
sistance, dyslipidaemia and hypertension. It is associated with 
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Summary
The metabolic syndrome is a very common disease associated with an increased risk of type 2 diabetes mellitus and cardiovascular disease. 
Disturbed lipoprotein metabolism characterized by elevated TAG, low HDL-cholesterol concentrations and insulin-resistance are the key 
features of the metabolic syndrome. Nutrition, especially the quality of dietary fat, plays an important role in the development and progression 
of the metabolic syndrome through infl uence on the expression of the gene encoding key regulatory enzymes of lipid and glucose metabolism. 
Dietary ω-6 and ω-3 PUFA reduce triglyceride accumulation in skeletal muscle, suppress hepatic lipogenesis, reduce hepatic triglyceride output 
and induce fatty acid oxidation in both liver and skeletal muscle, resulting in improvements of the metabolic syndrome. Genetic variation that 
predisposes to metabolic disturbances could interact with diet, modulating individual susceptibility to developing these conditions. Individuals 
with a ˝sensitive genotype˝ will be most susceptible to the impact of dietary therapy in order to reduce the risk of the metabolic syndrome.
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Sažetak
Metabolički sindrom je vrlo rasprostranjena bolest, povezana sa povećanim rizikom za razvoj šećerne bolesti tipa 2 i kardiovaskularnih 
bolesti. Narušen metabolizam lipoproteina, karakteriziran povećanjem nivoa ukupnih triglicerida i niskom koncentracijom HDL-kolesterola, 
te rezistencija na inzulin su ključne značajke metaboličkog sindroma. Prehrana, pogotovo sastav masnih kiselina u hrani, ima veliki utjecaj na 
razvoj metaboličkog sindroma. ω-6 i ω-3 polinezasićene masne kiseline snižavaju koncentraciju triglicerida u mišićima i izlučivanje triglicerida 
iz jetre, a povećavaju brzinu oksidacije masnih kiselina u jetri i mišićnom tkivu, djelovanjem na ekspresiju gena koji kodiraju za enzime ključne u 
regulaciji metabolizma lipida i glukoze, što u konačnici rezultira poboljšanjem simptoma metaboličkog sindroma. Individualna sklonost razvoju 
metaboličkog sindroma ovisi i o genetičkoj predispoziciji za metaboličke poremećaje. Osobe koje imaju genetičku predispoziciju za razvoj 
metaboličkog sindroma intenzivnije reagiraju na dijetalnu terapiju usmjerenu na smanjenje rizika za razvoj metaboličkog sindroma. 
Ključne riječi: metabolizam lipida, nezasićene masne kiseline, metabolički sindrom, osjetljivost na inzulin
a high risk of development of type 2 diabetes mellitus (T2DM) 
and cardiovascular disease (CVD) (Isomaa et al., 2001). The 
World Health Organization (WHO) have defi ned the metabolic 
syndrome as impaired insulin sensitivity, glucose intolerance 
or diabetes mellitus in combination with at least two other 
metabolic disorders including abdominal obesity, increased 
triacylglycerol (TAG) concentration, reduced HDL-cholesterol 
concentration and urinary microalbuminuria (Alberti and Zim-
met, 1998). The WHO estimates that the global prevalence of 
diabetes will double from 171 million people in 2000. to 366 
million in 2030. (Wild et al., 2005). One billion people in the 
world overweight and 300 million are considered obese. Es-
timates for 2030. are that 2 billion people will be overweight 
and 1.12 billion obese around the world (Kelly et al., 2008). 
Obesity is the principal etiological factor that predisposes to 
insulin resistance and the metabolic syndrome (Kahn and Flier, 
2000).  Prolonged excessive/imbalanced dietary fat intake and 
surplus adipose tissue initiate secretion of proinfl ammatory 
cytokines leading to disturbed fatty acid metabolism. Results 
are increased lipolysis, increased triacylglycerol (TAG) and 
nonesterifi ed fatty acids (NEFA) concentration. Subsequently, 
this results in accumulation of TAG and activated lipids in the 
form of long-chain fatty acyl-CoA esters, which disrupt normal 
metabolic functions in adipocytes, muscle, and liver (Unger, 
2002). These events fi nally lead to reduced insulin responsive-
ness, resulting in impaired insulin action, compensatory hyper-
insulinemia, and glucose intolerance (Saltiel, 2000; Roche et 
al., 2005; Guilherme et al., 2008). 
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Metabolic syndrome defi nition
The National Cholesterol Education Program’s Adult 
Treatment Panel III report (ATP III) identifi ed the metabolic 
syndrome as a multiplex risk factor for CVD (Grundy et al., 
2004). ATP III identifi ed 6 components of the metabolic syn-
drome that relate to CVD:
● Abdominal obesity
● Atherogenic dyslipidemia
● Raised blood pressure
● Insulin resistance - glucose intolerance
● Proinfl ammatory state
● Prothrombotic state
According to ATP III, underlying risk factors for CVD 
are obesity (especially abdominal obesity), physical inactiv-
ity, and atherogenic diet; the major risk factors are cigarette 
smoking, hypertension, elevated LDL cholesterol, low HDL 
cholesterol, family history of premature coronary heart disease 
(CHD), and aging; and the emerging risk factors include el-
evated triglycerides, small LDL particles, insulin resistance, 
glucose intolerance, proinfl ammatory state, and prothrombotic 
state. International Diabetes Federation (IDF) declares criteria 
fairly consistent with ATPIII (table 1.). Patients having at least 
3 of 5 characteristics (abdominal obesity, elevated triglycer-
ides, decreased HDL-cholesterol, increased blood pressure or 
increased fasting plasma glucose) can be diagnosed as having 
the metabolic syndrome.
Adipose tissue and insulin resistance
Insulin resistance (IR) is defi ned as decreased response to 
insulin, which leads to hyperinsulinemia. The main character-
istics of IR are disinhibited gluconeogenesis, impaired uptake 
of glucose by muscle and disinhibited lipolysis in adipose tis-
sue. The most important factor for IR development is obesity. 
Distribution of body fat mass is essential for eventual meta-
bolic complications since visceral and subcutaneous adipose 
tissues differ in their endocrine activities. Specifi c receptors 
such as angiotensin II receptors type-1 (AT1), β1-, β2- and β3-
adrenergic receptors, glucocorticoid and androgen receptors 
are represented to a larger degree in visceral adipose tissue 
where they promote lipolysis (Vohl et al., 2004). On the other 
hand, antilipolytic insulin receptors, α-2A adrenergic recep-
tors, and estrogen receptors are predominantly expressed in 
subcutaneous adipose tissue (Vohl et al., 2004). Additionally, 
visceral adipose secretes its products to the portal circulation, 
which brings the released FFA directly to the liver where they 
promote gluconeogenesis, VLDL synthesis, decrease glucose 
uptake and cause overall IR, while subcutaneous adipose tissue 
secretes higher level of leptin and adiponectin (Kershaw and 
Flier, 2004).
Insulin resistance is the link for different metabolic ab-
normalities clustering in the metabolic syndrome. It can be in-
duced by different factors, including dietary habits. High fat/ 
high energy diet is often associated with overweight. Excessive 
adipose tissue results in increased fatty acid fl ux to other tis-
sues and increased TAG storage in peripheral tissues, which 
promotes insulin resistance. Adipose tissue secretes several 
infl ammatory factors, collectively known as adipocytokines. 
The most important adipocytokines, which have a direct effect 
on insulin sensitivity include tumor necrosis factor α (TNF-α), 
leptin, interleukin 6 (IL-6), and adiponectin (Dandona et al., 
2004). 
TNF-α is the main factor triggering the secretion of FFA 
from adipose tissue into the circulation (Ruan and Lodish, 
2000). Obesity leads to an increased production of TNF-α 
which inhibits normal func-
tion of the insulin receptor (IR) 
(Hotamisigil, 2003). It has been 
demonstrated that knocking out 
the TNF-α and TNF-α receptor 
genes improves insulin resist-
ance in several animal models of 
obesity-associated insulin resist-
ance (Peraldi and Spiegleman, 
1998; Hotamisigil, 1999).
Leptin is a hormone secreted 
predominantly by adipose tissue 
and is a signal of energy      suffi -
ciency. Leptin has been shown to 
stimulate glucose uptake and fat-
ty acid oxidation (Wauters et al., 
2000). Furthermore, leptin mod-
ulates insulin secretion and ac-
tion via leptin receptors (LEPR) 
that are present in pancreatic β 
cells, adipose tissue, and muscle 
(Seufert et al., 1999). Several 
studies have shown that LEPR 
polymorphisms are associated 
with insulin and glucose metabo-
lism (Wauters et al., 2001), insu-
lin resistance (Chiu et al., 2004), 
and T2DM (Han et al., 2008).
Higher IL-6 levels have 
been associated with obesity and visceral fat deposition, in-
creased risk of impaired glucose tolerance, T2DM (Qi et al., 
2007; Stephens et al., 2007) and high blood pressure (Fernan-
dez-Real et al., 2001.). Visceral adipose tissue secretes about 
two to three times more IL-6 than subcutaneous tissue. IL-6 
inhibits insulin transduction in hepatocytes (Senn et al., 2002), 
adipogenesis and secretion of adiponectin (Kershaw and Flier, 
2004). 
Whilst most adipocytokines are associated with insulin 
resistance, greater levels of adiponectin are associated with im-
ATP III IDF 
Risk factor Defining level Defining level 
Abdominal obesity 
men             >102 cm 
women        >88 cm 
men              94 cm 
women         80 cm 
Triglycerides 1,7 mmol/L           1,7 mmol/L 
HDL-cholesterol 
men             1,03 mmol/L 
women       1,29 mmol/L 
men             1,03 mmol/L 
women       1,29 mmol/L 
Blood pressure 130/85  mmHg 130/85  mmHg or previously diagnosed 
hypertension
Fasting glucose 6,1 mmol/L 5,6  mmol/L or previously diagnosed 
T2DM
Table 1. Diagnostic criteria for metabolic syndrome according to ATPIII and IDF
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proved insulin sensitivity by reversing insulin resistance asso-
ciated with obesity and lipodystrophy (Yamauchi et al., 2001). 
Plasma adiponectin levels are inversely associated with several 
risk factors for the metabolic syndrome including adiposity, 
insulin resistance, increased blood pressure, TAG concentra-
tions and TNF-α receptor concentrations (Fernandez-Real et 
al., 2003). In the liver, it induces fatty acid oxidation, decreases 
lipid synthesis and uptake of FFA, and represses gluconeogen-
esis by enzyme down-regulation (Meier and Gressner, 2004). 
In muscle, adiponectin favors glucose and FFA oxidation. Adi-
ponectin concentrations are in negative correlations with trig-
lycerides and LDL-cholesterol, and positive correlations with 
whole-body fat oxidation and HDL levels (Trujillo et al., 2005; 
Abbasi et al., 2004).  Adiponectin exists in the form of low 
molecular weight (LMW) and high molecular weight (HMW) 
multimers. Pajvani et al. (2004) found that administration of 
HMW, but not LMW, adiponectin multimers lowered glucose 
in mice. In addition, the HMW: total adiponectin ratio but not 
total adiponectin, correlated with insulin sensitivity in humans 
and rodents (Pajvani et al., 2004). Insulin-resistant individu-
als and those with T2DM are found to have lower levels of 
the HMW multimer. The HMW: total adiponectin ratio is inde-
pendently correlated with concentrations of LDL and HDL par-
ticle, as well as LDL and HDL particle size. Individuals with a 
higher proportion of HMW adiponectin have higher concentra-
tions of less atherogenic LDL and higher concentrations of car-
dio protective HDL. Total adiponectin, and HMW and LMW 
adiponectin are all positively correlated with fat oxidation and 
negatively correlated with carbohydrate oxidation in resting 
humans (Lara-Castroa et al., 2007). Adiponectin inhibits con-
version of macrophages to foam cells and infl ammatory events 
in atherogenesis (Kershaw and Flier, 2004). Adiponectin also 
suppresses secretion of TNF-α (Aldhahi and Hamdy, 2003). 
Low adiponectin is associated with endothelial dysfunction in 
coronary vessels (Schachinger et al., 2000), and with the extent 
of coronary artery disease (von Eynatten et al., 2006).
Lipoprotein metabolism and metabolic syndrome
Dietary lipids are carried from the intestinal mucosa cells 
to other tissues by lipoproteins called chylomicrons. The prin-
ciple apoproteins of nascent chylomicrons are apo B-48, apo A-
I, apo A-II and apo-AIV. Apo B-48 is essential for chylomicron 
formation in the intestine. Apo B-48 is combined with lipid by 
the action of microsomal transfer protein. In circulation, the 
nascent chylomicrons acquire apo-C and apo-E from plasma 
HDL in exchange for phospholipids (Welty et al., 1999). Apo-
CII activate membrane bound lipoprotein lipase, LPL located 
on adipose and muscle tissues and bind chylomicrons to it. The 
fatty acids transported to the adipose cell are bound again into 
triacylglycerols and stored, while in the muscle the fatty acids 
are oxidized to provide energy. As the tissues absorb the fatty 
acids, the chylomicrons are reduced to cholesterol enriched 
remnants. As the chylomicron shrinks it transfers part of its 
phospholipids and apoproteins A and C to HDL. The apo-C 
proteins are continuously recycled between chylomicrons and 
HDL. The remnants lacking apo A and C proteins do not bind 
to the LPLs in the capillaries and are rapidly taken up by the 
liver via receptors that bind apo E (Welty et al., 1999). The 
liver synthesizes fatty acids and cholesterol and packages them 
for transport in the blood plasma in VLDLs. Apo B-100 is the 
major protein of VLDL. Apo B-100 is combined with lipid in 
the liver by the action of microsomal transfer protein (Welty 
et al., 1999). The nascent VLDL acquires apo-C and E from 
HDL. VLDLs bind to the same membrane bound lipoprotein 
lipases (LPLs) located on adipose and muscle tissues as chy-
lomicrons do. As the tissues absorb the fatty acids, the VLDLs 
progressively shrink to IDL and transfer a substantial portion 
of its phospholipids and apoprotein C to HDL. IDLs bind to 
receptors of liver cells where they are absorbed, or they can be 
further catabolized by LPLs, eventually loosing apo-E to form 
LDLs. Low-density lipoproteins (LDL) is the major choles-
terol carrying lipoprotein that carries cholesterol from the liver 
to the rest of the body (Welty et al., 1999). The sole protein of 
LDL is Apo B-100. LDL is cleared from plasma in part through 
the action of the LDL receptor (LDLR) by both the liver and 
peripheral cells. The structural requirements for binding LDL 
and VLDL differ: LDL binds its receptor via apoB-100, VLDL 
via apoE. After binding LDL the LDL receptors migrate to ar-
eas of the plasma membrane coated with the clathrin on the 
cytoplasmic side of it. The clathrin proteins promote endocyto-
sis. Once the vesicle is inside of the cell, the clathrin spontane-
ously dissociates from the endosomal vesicle, and lowered pH 
of the vesicle results in LDL dissociation from the receptor. 
The LDL receptors are recycled to the cell surface. The vesicle 
fuses with a lysosome which then degrades the lipoprotein to 
its primary components, fatty acids, glycerol, cholesterol and 
amino acids. The cholesterol is incorporated into the intracel-
lular cholesterol pool which is used for membrane or steroid 
synthesis. The liver also absorbs LDLs by the same endocyto-
sis mechanism. Approximately 75% of the LDLs are absorbed 
by the liver. High-density lipoproteins (HDL) scavenge choles-
terol from the bloodstream, from LDL, and from artery walls 
and ferry it back to the liver for disposal, so HDL cholesterol 
is often referred to as good, or protective, cholesterol. HDLs 
are secreted by liver and intestinal cells. The primary function 
of HDLs is to remove excess cholesterol and carry it to the 
liver to be metabolized into bile salts. HDL contains enzymes 
that either esterifi es cholesterol or transfer cholesteryl esters. 
Apo AI is essential for HDL formation because in its absence 
no HDL is present in plasma (Ordovas et al., 1989). The liver 
and intestine synthesize apolipoprotein A-I (apo A-I), which 
can interact with the adenosine triphosphate–binding cassette 
transporter A1 (ABCA1) located on the arterial macrophages, 
transporting free cholesterol to the extracellular HDL. Lipi-
dation of the HDL particles generates nascent HDL (Curtiss 
et al., 2006). Subsequently, lechithincholesterol transferase 
(LCAT), enzyme that circulates with HDL, esterifi es free cho-
lesterol within nascent HDL with long chain fatty acids from 
phospholipids to produce mature HDL particles. These mature 
HDL particles can further take up free cholesterol. LCAT thus 
facilitating the storage and transport of excess cholesterol. Ma-
ture HDL has at least 2 metabolic fates. In the direct pathway, 
cholesteryl esters contained within HDL can undergo selective 
uptake by hepatocytes and steroid hormone–producing cells 
via the scavenger receptor type B1 and subsequent excretion 
into the bile (Lewis and Rader, 2005). In the indirect pathway, 
cholesteryl esters within HDL can be exchanged for triglyc-
erides in apolipoprotein B–rich particles (LDL and VLDL) 
through the action of cholesteryl ester transfer protein (CETP), 
which is another peripheral protein that circulates with HDL. 
CETP promotes the net transfer of cholesterol esters from HDL 
to LDL, IDL and VLDL. This process transforms VLDLs and 
IDLs into LDLs. The triglyceride-rich HDL can then undergo 
hydrolysis by hepatic lipase and endothelial lipase to form 
small HDL for further participation in transport (Lewis and 
Rader, 2005). In addition to its major role in reverse choles-
terol transport, HDL has other biological activities. These in-
clude antioxidant (counteracting LDL oxidation) effects, anti-
infl ammatory effects, antithrombotic/profi brinolytic (reducing 
R. TEPARIĆ et al.: Croatian Journal of Food Technology, Biotechnology
and Nutrition 7 (1-2), 69-77 (2012)
CROATIAN JOURNAL OF FOOD TECHNOLOGY, BIOTECHNOLOGY AND NUTRITION
72
platelet aggregation and coagulation) effects, and vasoprotec-
tive (facilitating vascular relaxation and inhibiting leukocyte 
chemotaxis and adhesion) effects (Assmann and Gotto, 2004; 
Navab et al., 2004).
Recent studies have shown that increased liver fat con-
tent is associated with overproduction of triglyceride-rich large 
VLDL particles in humans (Adiels et al., 2006). Major role in 
the catabolism of triglyceride-rich lipoproteins plays lipopro-
tein lipase (Nilsson-Ehle et al., 1980; Beisiegel et al., 1991). 
Generation of small dense LDL occurs as a result of distur-
bances in lipid metabolism, which are characteristic of T2DM, 
obesity, insulin resistance, and CVD (Packard, 2003).
Increased plasma cholesteryl ester transfer protein activ-
ity enhances lipid exchange, which removes cholesteryl ester 
from the LDL particle core, and replaces it with triglycerides 
from VLDL and chylomicrons. LDL, enriched with 
triglycerides, becomes a good substrate for hepatic 
lipase. If hepatic lipase activity is suffi ciently high, 
hepatic lipase-mediated hydrolysis of triglycerides 
on triglyceride-rich LDL will generate small dense 
LDL particles (Chung et al., 1998). Some stud-
ies have demonstrated that hepatic lipase was the 
strongest contributor to small dense LDL levels, 
whereas lipoprotein lipase activity was associated 
with an increase in large buoyant LDL particles 
(Carr et al., 2002).  
Plasma HDL levels are regulated by the he-
patic and intestinal synthesis of apolipoprotein A-I, 
and by the rate of HDL maturation and catabolism 
(Zannis et al., 2006). Hepatic lipase activity is also a 
major determinant of HDL-cholesterol levels (Col-
let et al., 1999). In insulin resistance and T2DM, 
the abnormal HDL subclass distribution (Lara-Cas-
tro et al., 2006; Okamoto et al., 2002) accelerates 
atherosclerosis by reducing the effl ux of cholesterol 
from macrophage foam cells.
Dietary fat and metabolic syndrome
Disturbed lipoprotein metabolism characterized by ele-
vated TAG and low HDL-cholesterol concentrations, and insu-
lin-resistance are the key features of the metabolic syndrome. 
Plasma low-density lipoprotein (LDL)-cholesterol concentra-
tions are often normal, but there is a relative increase of small, 
dense, atherogenic particles. Dietary ω-6 and ω-3 PUFA re-
duce triglyceride accumulation in skeletal muscle (Baur et al., 
1998) that is associated with improvements of the metabolic 
syndrome (Clarke, 2000). Ingestion of fats rich in ω-6, and par-
ticularly ω-3 PUFA, suppress hepatic lipogenesis (Jump and 
Clarke, 1999), reduce hepatic triglyceride output (Nestel et al., 
1984) and induce fatty acid oxidation in both liver and skel-
etal muscle (Thomassen et al. 1982; Power and Newsholme, 
1997). 
Insulin sensitivity is affected by the quality of dietary fat, 
independently of its effects on body weight. Saturated fat sig-
nifi cantly worsens insulin-resistance, while monounsaturated 
and polyunsaturated fatty acids improve it. Fatty acids play a 
role in both the cellular and molecular mechanisms of insulin 
resistance, because they are a determinant of the membrane 
property that affects insulin sensitivity (Ginsberg et al., 1982), 
and they act as a physiological signaling molecule that induces 
insulin resistance (Griffi n et al., 1999).
Vessby et al. (2001) has demonstrated that decreasing 
dietary SFA and increasing MUFA improves insulin sensitiv-
ity but has no effect on insulin secretion. Perez-Jimenez et 
al. (2001) have shown that isoenergetic substitution of SFA 
by MUFA markedly improves insulin sensitivity. In contrast, 
Lovejoy et al. (2002) have failed to show any marked effect of 
high-MUFA, high-SFA or trans-fatty acid-rich diets on insu-
lin sensitivity. A number of positive health benefi ts relevant to 
the metabolic syndrome have been associated with increased 
long-chain (LC) ω-3 PUFA intake, particularly in relation to 
TAG metabolism (Roche and Gibney, 2000). Animal studies 
show that feeding LC ω-3 PUFA has positive effects on glu-
cose metabolism and insulin resistance (Aguilera et al., 2004). 
The health impact of increased LC ω-3 PUFA consumption on 
insulin resistance in human subjects is not clear yet since some 
intervention studies have reported positive effects on insulin 
sensitivity in individuals with impaired glucose tolerance and 
diabetes (Fasching et al., 1991), while other studies have not 
(Vessby et al., 2001; Brady et al., 2004).
The search for the genetic basis of obesity and insulin 
resistance is fundamental to the understanding of the effects 
of dietary fatty acids and the metabolic syndrome. PUFA ex-
ert their benefi cial effects by up-regulating the expression of 
genes encoding proteins involved in fatty acid oxidation (table 
2.) by activating the transcription factor peroxisome prolifera-
tor-activated receptor α (PPARα). Simultaneously PUFA sup-
press expression of genes encoding proteins of lipid synthesis 
(table 2.) by reducing the nuclear abundance and DNA-binding 
affi nity of factors responsible for imparting insulin and car-
bohydrate control to lipogenic and glycolytic genes (Clarke, 
2001). The outcome is an improvement in the symptoms of the 
metabolic syndrome and a reduced risk of heart disease. One 
of the fi rst PUFA-dependent repartitioning of lipid metabolism 
involves inhibition of the production of hepatic malonyl-CoA 
(Wilson et al., 1990). Since malonyl-CoA acts as an inhibitor 
of carnitine palmitoyltransferase this effect leads to enhanced 
fatty acid oxidation by increasing fatty acid entry into the mito-
chondria and peroxisomes (Zammit, 1999). In parallel PUFA-
dependent induction of genes encoding proteins involved in 
fatty acid oxidation and ketogenesis occurs (Clarke, 2000; 
Jump and Clarke, 1999; Clarke et al., 1999). 
The interaction of PPARα with its DNA recognition site is 
markedly enhanced by ligands such as the conjugated linoleic 
acid and PUFA (Zammit, 1999; Issemann and Green, 1990). 
In general, PPARα activation leads to the induction of several 
hepatic, cardiac and skeletal muscle genes encoding proteins 
involved in lipid transport, oxidation and thermogenesis, in-
cluding carnitine palmitoyltransferase, peroxisomal acyl-CoA 
Table 2. Survey of enzymes included in lipid metabolism coded by genes whose 
expression is down- or up- regulated by PUFA
PUFA
SUPPRESSION INDUCTION 
glucokinase carnitine palmitoyltransferase 
pyruvate kinase acyl-CoA oxidase 
glucose-6-phosphate dehydrogenase uncoupling protein-3 
citrate lyase  
acetyl-CoA carboxylase  
fatty acid synthase  
stearoyl-CoA desaturase  
-6 and -5 desaturases  
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oxidase and uncoupling protein-3 (Clarke, 2000; Aoyama et 
al., 1998;  Xu et al., 1999). PUFA metabolites such as eicosa-
noids or oxidized fatty acids are even far more potent tran-
scriptional activators of PPARα-dependent genes (Krey et al., 
1997; Lee at al. 2011). Hyperglycemia was found to suppress 
PPARα expression and induce PPARγ expression, increase β-
cell and cardiomyocyte lipids and accelerate cell death (Zhou 
et al., 2000). PPARγ plays a critical role in adipogenesis, in-
sulin sensitivity and blood pressure (Barroso et al., 1999; Lee 
at al. 2011).
Dietary PUFA inhibit hepatic lipogenesis by suppress-
ing the expression of hepatic enzymes involved in fatty acid 
biosynthesis and glucose metabolism, including glucokinase, 
pyruvate kinase, glucose-6-phosphate dehydrogenase, citrate 
lyase, acetyl-CoA carboxylase, fatty acid synthase, stearoyl-
CoA desaturase and the Δ-6 and Δ-5 desaturases (Duplus et al., 
2000; Cho et al., 1999).
SREBP are a family of transcription factors that were fi rst 
isolated as a result of their properties for binding to the sterol 
regulatory element (Osborne, 2000; Brown and Goldstein, 
1999). PUFA rapidly reduce the nuclear content of hepatic 
SREBP-1a, acting as a regulator of genes encoding proteins 
involved in both lipogenesis and cholesterogenesis. SREBP-2 
is a regulator of genes encoding proteins involved in cholester-
ol metabolism (Osborne, 2000; Brown and Goldstein, 1999). 
Diets rich in 18:2(ω-6) or 20:5 and 22:6(ω-3) were found to 
reduce the hepatic nuclear and precursor content of mature 
SREBP-1 by 65 and 90% and by 60 and 75%, respectively (Xu 
et al., 1999). The decrease in SREBP-1 was accompanied by 
a comparable decrease in the transcription rate of hepatic fatty 
acid synthase (Xu et al., 1999). 
Group of fatty acids, known as conjugated linoleic acid 
(CLA), in particular the cis-9, trans-11-CLA isomer, may have 
the potential to improve lipid and insulin metabolism (Roche et 
al., 2002; Moloney et al., 2004). This effect has been ascribed 
to differential SREBP-1c gene expression, a regulatory tran-
scription factor involved in lipogenesis and glucose metabo-
lism (Foretz et al., 1999; Gosmain et al., 2004). Feeding a cis-
9, trans-11-CLA isomer-rich diet has divergent tissue-specifi c 
effects on SREBP-1c expression, markedly reducing hepatic 
SREBP-1c and increasing adipose tissue SREBP-1c expres-
sion, both of which could contribute to improved lipid and glu-
cose metabolism (Roche et al., 2002). This study has  shown 
TNF-α-regulated SREBP-1c expression in human adipocytes, 
but not in hepatocytes (Roche et al., 2002), supporting the hy-
pothesis for cross-talk between molecular markers of insulin 
sensitivity and adipocytokines, which in turn can be modifi ed 
by fatty acids. 
Unlike PUFA, saturated and monounsaturated fatty acids 
had no effect on the concentration of SREBP-1 or on lipogenic 
gene expression (Xu et al., 1999; Worgall et al., 1998; Hannah 
et al., 2001). 
Dietary treatment of MS
The aim of dietary treatment of the metabolic syndrome is 
to improve insulin sensitivity, lipid metabolism and the associ-
ated cardiovascular abnormalities. It is not necessary to achieve 
the ideal BMI to improve the metabolic profi le. Weinstock et 
al. (1998) showed that 5–10% weight reduction is suffi cient to 
induce a clinically relevant effect. Many studies recorded the 
improvement of insulin sensitivity due to weight reduction was 
higher than that obtained with insulin-sensitizing drugs. The 
benefi cial effects of weight reduction are usually preserved as 
long as weight is not regained. Fat intake is positively corre-
lated with plasma insulin values and negatively with insulin 
sensitivity. However, high monounsaturated fat diet improves 
insulin sensitivity compared to a high-saturated-fat diet only 
if total fat intake does not exceed 38% of total energy (Vessby 
et al., 1999). Salt, alcohol and carbohydrates are other dietary 
components that infl uence insulin sensitivity, plasma triglyc-
eride level and blood pressure. Since glucose and lipid me-
tabolism are strongly related, any derangement of carbohy-
drate metabolism induced by a high-carbohydrate diet will 
also increase plasma triglycerides and decrease plasma HDL 
concentrations (Garg, 1998). Optimal diet for people with the 
metabolic syndrome has to reduce plasma cholesterol levels 
and LDL as much as possible. The diet should be limited in the 
intake of saturated fat, to avoid unfavorable effects on insulin 
sensitivity, blood pressure and plasma lipids. High fi bre/low-
GI foods should be used without specifi c limitations instead of 
carbohydrate-rich foods with a high GI. Moderate amounts of 
fat containing MUFA and PUFA could be permitted since they 
do not induce detrimental metabolic effects. 
Unsaturated fats are predominantly found in vegetable 
oils, nuts, and seeds. MUFAs are found in high concentrations 
in canola, peanut and olive oils, avocados, almonds, hazelnuts, 
pumpkin and sesame seeds. About 50% of monounsaturated 
fatty acids are provided by animal products, primarily meat 
fat. The major monounsaturated fatty acid in the diet is oleic 
acid. The overall data indicate that monounsaturated fats do 
not lower LDL or HDL cholesterol relative to saturated fat as 
much as does polyunsaturated fat (Mensink and Katan, 1992; 
Valsta et al., 1992). The saturated fat and monounsaturated fat 
contents of most natural diets are similar, and when saturated 
fat is restricted, the monounsaturated fat content of the diet 
decreases.
PUFAs are found in high concentrations in sunfl ower, 
corn, soybean, and fl axseed oils, and also in foods such as wal-
nuts, fl ax seeds, and fi sh. The major ω-6 fatty acid in the diet is 
α-linoleic acid, which serves as the precursor for arachidonic 
acid (20:4ω-6), which has important biological effects in the 
body. α-linoleic acid could not be synthesized by the human 
body and is therefore an essential fatty acid. The other ma-
jor essential fatty acid in the diet is α-linolenic acid (18:3ω-3). 
This fatty acid can be rapidly converted in the body to eicos-
apentaenoic acid (20:5ω-3), which can be further elongated, 
desaturated, and oxidized to docosahexaenoic acid (22:6ω-3) 
(Siguel et al., 1987). Sources of ω-6 polyunsaturated fatty ac-
ids include nuts, seeds, certain vegetables, and vegetable oils 
such as soybean oil, sunfl ower oil, and corn oil. Certain oils, 
such as blackcurrant seed oil and evening primrose oil, are 
high in γ-linolenic acid (18:3ω-6). Arachidonic acid is formed 
from linoleic acid in animal cells, but not plant cells, and is 
present in the diet in small amounts in meat, poultry, and eggs. 
Most ω-6 polyunsaturated fatty acids are consumed in the form 
of linoleic acid. Other ω-6 polyunsaturated fatty acids, such 
as arachidonic acid and γ-linolenic acid, are present in small 
amounts in the diet. 
ω-3 fats are an important type of polyunsaturated fat the 
human body can’t make, so they must come from food. The 
major sources of ω-3 fatty acids include certain vegetable 
oils and fi sh (Kris-Etherton et al., 2000). Vegetable oils such 
as soybean and fl axseed oils contain high amounts of α-lino-
lenic acid. Fish oils provide a mixture of eicosapentaenoic acid 
(EPA) and docosahexaenoic acid (DHA), so fatty fi sh are the 
major dietary sources of EPA and DHA. Smaller amounts are 
also present in meat and eggs. ω-3 Fatty acids found in fi sh oil, 
especially eicosapentaenoic acid, lower triacylglycerol con-
centrations signifi cantly and reduce coronary heart disease risk 
as well, independently of their infl uence on lipoprotein con-
centrations (Harris, 1997). 
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The average concentration of conjugated linoleic acid 
(CLA) in dairy products and ruminant meats is approximately 
5 mg of CLA/g of fat (Chin et al., 1992). Although numerous 
CLA isomers have been reported to be found in meat, milk, 
and dairy products (Ha et al., 1989), the cis-9,trans-11 isomer 
is the predominant form of CLA present in these foods (Ma et 
al., 1999). The conjugated linoleic acid content of milk can 
vary depending on a number of factors, such as animal feed 
diet, supplement use, and number of lactations (MacDonald, 
2000). Ma  et al. (1999) reported values of 1.8 mg of CLA/g of 
fat for skim milk, 3.4 mg/g for whole milk, 4.3 mg/g for 1% fat 
milk, 5.0 mg/g for 2% fat milk, and 5.5 mg/g for half-and-half 
cream. In addition, values ranged from 2.7 to 6.2 mg of CLA/g 
of fat for various cheeses and 1.2 to 3.2 mg of CLA/g of fat for 
different types of raw and cooked beef products.
Conclusion
The metabolic syndrome (MS) is a multi-component 
metabolic disorder associated with a high risk of development 
of T2DM and CVD. Insulin resistance is the link for different 
metabolic abnormalities clustering in the metabolic syndrome. 
It can be induced by different factors, including dietary habits. 
Obesity is concerned to be the principal aetiological factor that 
predisposes to insulin resistance and the metabolic syndrome. 
Adipose tissue secretes several infl ammatory factors, collec-
tively known as adipocytokines, which have a direct effect on 
insulin sensitivity. Many studies recorded that the improve-
ment of insulin sensitivity due to weight reduction is higher 
than that obtained with insulin-sensitizing drugs. Insulin sensi-
tivity is affected by the quality of dietary fat, independently of 
its effects on body weight. Saturated fat worsen insulin-resist-
ance, while unsaturated fatty acids, especially PUFA,  improve 
it on molecular level infl uencing the DNA-binding activity and 
abundance of transcription factors included in regulation of the 
expression of genes encoding key regulatory enzymes of lipid 
and glucose metabolism. 
Furthermore, there is evidence that genetic variation that 
predisposes to metabolic disturbances could interact with diet, 
modulating individual susceptibility to developing these con-
ditions. Individuals with a ˝sensitive genotype˝ will be most 
susceptible to the impact of dietary therapy in order to reduce 
the risk of the metabolic syndrome. 
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